Sophia Genetics to Commercialize MSK-ACCESS Clinical Liquid Biopsy Test
The collaboration between Sophia and Memorial Sloan Kettering Cancer Center aims to offer new testing and analytics capabilities to clinicians and researchers.
NewStem, MSK Innovation Hub Team to Validate Cancer Diagnostics Software Platform
The Israeli startup called this collaboration a necessary step toward commercializing its CE-marked NewStem Software Diagnostic Device for reducing oncology drug resistance.
Sophia Genetics Partners With MSK on Clinical Decision Support, Boundless Bio on ecDNA Detection
Sophia will provide Memorial Sloan Kettering with predictive tumor analysis technology and help startup Boundless develop new therapies and MDx methods.
Biodesix, Memorial Sloan Kettering Team on Minimal Residual Disease Test
The MRD test will run on the Bio-Rad QX600 ddPCR System, and Biodesix may develop more tests for MSK under the agreement.
The lead investigators have also spun out a company, Isabl, aiming to make the approach available to the broader community.